ARG1 and cancer: Arg1 inhibitors are currently in early phase clinical trials in cancer (Calithera/Incyte (39, 40)), while the replenishment of arginine or arginine precursors has been tested in sickle cell disease resulting in a significant reduction in vaso-occlusive complications (41, 42).